DR. CRAIG W CARSON, M.D.
Osteopathic Medicine at Renaissance Blvd, Edmond, OK
License number
Oklahoma 17781
Category
Osteopathic Medicine
Type
Rheumatology
Address
Address
1701 Renaissance Blvd SUITE 110, Edmond, OK 73013
Phone
(405) 844-4978
(405) 844-0562 (Fax)
(405) 844-0562 (Fax)
Personal information
See more information about CRAIG W CARSON at radaris.comName
Address
Phone
10 Easy St, Clinton, OK 73601
2401 Ashecroft Cir, Edmond, OK 73034
1701 Renaissance Blvd, Edmond, OK 73013
2401 Ashecroft Cir, Edmond, OK 73034
Clinton, OK
Professional information
Craig W Carson, Edmond OK
Specialties:
Rheumatologist
Address:
1701 Renaissance Blvd, Edmond, OK 73013
Education:
University of Utah, School of Medicine - Doctor of Medicine
The Mayo Clinic - Fellowship - Rheumatology (Internal Medicine)
The Mayo Clinic - Residency - Internal Medicine
The Mayo Clinic - Fellowship - Rheumatology (Internal Medicine)
The Mayo Clinic - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Rheumatology (Internal Medicine)
Craig Weldon Carson, Edmond OK
Specialties:
Internal Medicine, Rheumatology, Pediatric Rheumatology
Work:
OU Medical Center Edmond
1701 Renaissance Blvd, Edmond, OK 73013
1701 Renaissance Blvd, Edmond, OK 73013
Education:
University of Utah (1985)
Method For Regulating Inflammation And Tumor Growth With Calmodulin, Calmodulin Analogues Or Calmodulin Antagonists
US Patent:
5698518, Dec 16, 1997
Filed:
Mar 30, 1994
Appl. No.:
8/220814
Inventors:
Craig W. Carson - Edmond OK
Charles T. Esmon - Oklahoma City OK
Donald S. Houston - Oklahoma City OK
Charles T. Esmon - Oklahoma City OK
Donald S. Houston - Oklahoma City OK
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
C07K 14435, C07K 14525
US Classification:
514 12
Abstract:
A method of treating patients to inhibit inflammation is disclosed. In the method, an effective amount of calmodulin, a calmodulin analogue or calmodulin receptor agonist is administered to a patient to inhibit production of tumor necrosis factor and/or augment elastase. In another method, an effective amount of calmodulin antagonist is administered to a patient to stimulate immune response or inhibit elastase release. In another embodiment, a diagnostic test is disclosed to be used on patient blood samples to determine individual propensity to regulate tumor necrosis factor and/or elastase by calmodulin, its analogues or receptor agonists.
Method For Detecting Antibodies To Thrombomodulin In Patients
US Patent:
5639625, Jun 17, 1997
Filed:
Sep 26, 1994
Appl. No.:
8/312870
Inventors:
Craig W. Carson - Edmond OK
Charles T. Esmon - Oklahoma City OK
Charles T. Esmon - Oklahoma City OK
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
International Classification:
G01N 3353
US Classification:
435 792
Abstract:
A novel method of detecting antibodies to thrombomodulin in plasma or serum as an indication of an individual's propensity to thrombosis or inflammation is disclosed. A method for identifiying patients at risks of thrombosis or glomerular nephritis by monitoring autoantibodies to truncated soluble thrombomodulin is revealed. A preferred method is an ELISA assay to detect antibodies to thrombomodulin.